Andreas Schulte-Mecklenbeck

TL;DR: A single-cell characterization of cerebrospinal fluid and blood of newly diagnosed multiple sclerosis patients is provided, revealing altered composition of lymphocyte and monocyte subsets, validated by other methods including the interrogation of the TFH subset in mouse models of MS.

TL;DR: Investigating the peripheral blood and cerebrospinal fluid of MS patients treated with natalizumab revealed that transmigration of this subset depends on the α4β1 integrin very late antigen (VLA)-4, and no MS-related changes in the migratory capacity of NK cells were observed, but NK cells derived from patients with MS exhibit a reduced cytolytic activity in response to antigen-activated CD4+ T cells.

TL;DR: The data demonstrate that DMF treatment of patients with MS affects predominantly memory T cells accompanied by a shift in TH cell populations, resulting in a shift toward anti-inflammatory responses, and indicates that monitoring of memory subsets might enhance vigilance of impaired antiviral immunity.

TL;DR: Data demonstrate that high-affinity T cells preferentially use mitochondrial respiration, which is then inhibited by teriflunomide, and point to a mechanism of action where DHODH inhibition corrects metabolic disturbances in T cells, which primarily affects profoundly metabolically active high-Affinity T cell clones.

TL;DR: It is suggested that remodeling of the innate immune compartment may promote long-term efficacy of alemtuzumab and preserve immunocompetence in patients with MS.